Abstract 401P
Background
E7386, a novel oral anticancer agent, inhibits β-catenin binding to its transcriptional co-activator, CBP, thus modulating Wnt/β-catenin signaling. The objectives of the dose-escalation part in this phase 1b study were to assess safety, tolerability, pharmacokinetics (PK), biomarkers, and preliminary efficacy of E7386 combined with lenvatinib in pts with advanced hepatocellular carcinoma or other solid tumors (ST). We present the results from the ST subpart.
Methods
In cycle 0, E7386 was administered orally in escalating doses once daily (QD) or twice daily (BID) for 5 or 6 days. From cycle 1 day 1, E7386 QD or BID, combined with lenvatinib 20 mg QD, were administered on a continuous schedule in 28-day cycles. Tolerability was evaluated with a 3+3+3 design. Adverse events (AEs) were graded using CTCAE v5.0. No prophylactic treatment was allowed during the dose-limiting toxicity (DLT) evaluation period. Tumor response was assessed by investigators using RECIST v1.1. PK and biomarker analyses were conducted using samples collected at defined time points.
Results
As of data cutoff (24 May 2022), 36 pts had been treated in the ST subpart with E7386 dose ranges from 10 to 160 mg QD and from 100 to 120 mg BID. Generalized edema (grade 3) and liver disorder (grade 4) were DLTs noted in 1 of 6 pts each in the 15 mg QD and 120 mg BID cohorts, respectively. The most common treatment-emergent AEs (TEAEs; ≥50% of pts) were nausea (72.2%), vomiting (58.3%), hypertension (58.3%), diarrhea (58.3%), and proteinuria (52.8%). The most common grade ≥3 TEAEs (≥10% of pts) were proteinuria (19.4%) and gamma-glutamyltransferase increased (11.1%). Serious TEAEs (≥5% of pts) were biliary tract infection (5.6%) and hepatic infection (5.6%). Among 34 pts who had ≥1 tumor assessment after study-drug administration, 6 partial responses (2 biliary tract carcinoma, 2 neuroendocrine tumor, 2 thymic cancer) were observed regardless of wnt related gene mutation. Cmax and AUC for E7386 increased with increasing E7386 dose.
Conclusions
E7386 120 mg BID, in combination with lenvatinib 20 mg QD, was deemed tolerable and manageable with antiemetic administration and determined as the recommended dose for the expansion part.
Clinical trial identification
NCT04008797.
Editorial acknowledgement
Medical writing support was provided by Jeffrey Bratz, PhD, of Oxford PharmaGenesis Inc., Newtown, PA, USA, with funding by Eisai Inc., Nutley, NJ, USA.
Legal entity responsible for the study
Eisai Inc.
Funding
Eisai Inc., Nutley, NJ, USA.
Disclosure
S. Kondo: Financial Interests, Personal, Invited Speaker: Incyte, Chugai; Financial Interests, Personal, Expert Testimony: Takeda; Financial Interests, Institutional, Invited Speaker: Eisai, Asteras, Incyte, Eli Lilly, AstraZeneca, AbbVie. T. Koyama: Financial Interests, Personal, Invited Speaker: Chugai, Sysmex; Financial Interests, Personal, Research Grant: PACT Pharma, Lilly, Daiichi Sankyo, Novartis, Takeda. A. Kawazoe: Financial Interests, Personal, Invited Speaker: Daiichi Sankyo, Lilly, Ono, Taiho, Bristol Myers Squibb, Merck Serono; Financial Interests, Institutional, Research Grant: Ono, MSD, Taiho, Bayer, Sumitomo Dainippon, AstraZeneca. S. Iwasa: Financial Interests, Institutional, Research Grant: Eisai. K. Yonemori: Financial Interests, Personal, Advisory Board: Novartis, Eisai, AstraZeneca, Chugai, Takeda, Genmab, OncXerna; Non-Financial Interests, Institutional, Principal Investigator: MSD, Daiichi Sankyo, AstraZeneca, Taiho, Pfizer, Novartis, Takeda, Chugai, Ono, Sanofi, Seattle Genetics, Eisai, Eli Lilly, Genmab, Boehringer Ingelheim, Kyowa Hakko Kirin, Nihon Kayaku, Haihe; Financial Interests, Personal, Other, Honorarium for lecture: Pfizer, Eisai, AstraZeneca, Eli Lilly, Takeda, Chugai, Fuji Film Pharma, MSD, Boehringer Ingelheim, Ono, Daiichi-Sankyo. K. Shitara: Financial Interests, Personal, Advisory Board: Lilly, Bristol Myers Squibb, Takeda, Pfizer, Ono Pharmaceutical, MSD, Taiho Pharmaceutical, Novartis, AbbVie, GlaxoSmithKline, Daiichi Sankyo, Amgen, Boehringer Ingelheim, Guardant Health Japan Corp, Astellas Pharma Inc.; Financial Interests, Personal, Invited Speaker: Takeda Pharmaceutical Company Limited, Bristol Myers Squibb, Janssen Pharmaceutical K.K.; Financial Interests, Institutional, Research Grant: Astellas, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Chugai Pharmaceutical, MSD, Eisai, Amgen. Y. Nakamura: Financial Interests, Personal, Invited Speaker: Chugai, Merck Biopharma, Guardant Health AMEA; Financial Interests, Institutional, Funding: Taiho, Chugai, Guardant Health, Genomedia, Daiichi Sankyo, Roche Diagnostics; Financial Interests, Institutional, Invited Speaker: Seagen. N. Yamamoto: Financial Interests, Personal, Invited Speaker: Pfizer, AstraZeneca, Eli Lilly, Ono, Chugai, Sysmex, Daiichi Sankyo; Financial Interests, Personal, Advisory Board: Eisai, Takeda, Otsuka, Boehringer Ingelheim, Cimic, Chugai; Financial Interests, Institutional, Invited Speaker, Principal Investigator in industry sponsored trial: Astellas, Chugai, Eisai, Taiho, BMS, Pfizer, Novartis, Eli Lilly, AbbVie, Daiichi Sankyo, Bayer, Boehringer Ingelheim, Kyowa-Hakko Kirin, Takeda, ONO, Janssen Pharma, MSD, Merck, GSK, Sumitomo Dainippon, Chiome Bioscience, Otsuka; Financial Interests, Institutional, Invited Speaker, Principal investigator in industry sponsored trial: Carna Biosciences, Genmab, Shionogi, TORAY. T. Sahara, N. Hayata, S. Yamamuro, T. Kimura, L. Dutta, T. Tamai: Financial Interests, Personal, Full or part-time Employment: Eisai. M. Ikeda: Financial Interests, Personal, Advisory Board: AstraZeneca, Chugai, Eli Lilly Japan, Eisai, NIHON Servier, Novartis, Ono, Takeda, GlaxoSmithKline; Financial Interests, Personal, Invited Speaker: AstraZeneca, Bayer, Bristol Myers Squibb, Chugai, Eli Lilly Japan, Eisai, NIHON Servier, Novartis, Taiho, Yakult, Teijin Pharma, AbbVie, Abbott Japan, Fujifilm Toyama Chemical, Incyte Biosciences Japan, ASLAN, Chugai, NIHON Servier, Takeda; Financial Interests, Institutional, Invited Speaker: Bayer, Bristol Myers Squibb, Eisai, AstraZeneca, Eli Lilly Japan, Chugai Pharmaceutical, Merck Serono, MSD, Ono, Yakult, Novartis, Takeda, J-Pharma, Pfizer, Chiome Bioscience, NIHON Servier, Delta-Fly Pharma, Syneos Health, Merus.N.V. All other authors have declared no conflicts of interest.
Resources from the same session
430P - Single-cell spatial architecture of tumour microenvironment in patients with in-transit melanoma (ITM)
Presenter: Camelia Quek
Session: Poster viewing 06
431P - Alveolar soft part sarcomas: A tertiary care Indian centre experience
Presenter: Jyoti Bajpai
Session: Poster viewing 06
432P - Representation of countries and gender in abstracts at the 2022 American Society of Clinical Oncology Annual Scientific Meeting (ASCO ASM)
Presenter: Laure-Anne Teuwen
Session: Poster viewing 06
433P - Variations in radiation oncology treatment access in Asia and its implications on cancer care
Presenter: Abhishek Krishna
Session: Poster viewing 06
434P - Outcome of high grade glioma patients: A single institution experience
Presenter: Adeeba Zaki
Session: Poster viewing 06
435P - The pattern of presentation of cancer in young adults from a tertiary care centre: A cause for concern
Presenter: Deepa Joseph
Session: Poster viewing 06
436P - Oncologic outcomes in patients with extraskeletal Ewing’s sarcoma (EES): A tertiary care centre experience
Presenter: Ashish Gulia
Session: Poster viewing 06
437P - The prevalence of burnout among medical oncology fellows-in-training in the Philippines: A cross-sectional study
Presenter: Daphne Lee
Session: Poster viewing 06
438P - Estimating scenarios for survival time in patients with metastatic melanoma receiving immunotherapy or targeted therapy
Presenter: Megan Smith-Uffen
Session: Poster viewing 06
439P - Evaluating Ewing’s sarcoma as the prototype for cancer care in teenage and young adults (TYA): A single-center retrospective cross-sectional study
Presenter: Pradeep Kumar Kistampally
Session: Poster viewing 06